CONDENSED BALANCE SHEETS (Unaudited) (USD $)	Jun. 30, 2011	Dec. 31, 2010
Current assets:
Cash and cash equivalents	$ 7,023,176	$ 6,324,430
Marketable securities	19,076,620	20,567,861
Proceeds from sale of RXi, received January 6, 2011	0	6,938,603
Receivable	107,907	259,006
Investment in Adventrx Pharmaceuticals, at market	379,260	0
Income taxes recoverable	0	519,158
Interest receivable	105,334	117,624
Prepaid expenses and other current assets	1,803,333	1,247,145
Total current assets	28,495,630	35,973,827
Equipment and furnishings, net	294,873	319,191
Goodwill	183,780	183,780
Other assets	214,729	220,292
Total assets	29,189,012	36,697,090
Current liabilities:
Accounts payable	1,433,782	1,027,924
Accrued expenses and other current liabilities	4,130,042	2,663,910
Warrant liabilities	1,259,518	2,437,281
Total current liabilities	6,823,342	6,129,115
Stockholders' equity:
Preferred Stock, $.01 par value, 5,000,000 shares authorized, including 15,000 shares of Series A Junior Participating Preferred Stock; no shares issued and outstanding	0	0
Common stock, $.001 par value, 175,000,000 shares authorized; 109,857,885 and 109,840,445 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively	109,858	109,840
Additional paid-in capital	230,066,850	229,253,122
Accumulated comprehensive income, net of tax	379,260	0
Treasury stock, at cost (633,816 shares)	(2,279,238)	(2,279,238)
Accumulated deficit	(205,911,059)	(196,515,749)
Total stockholders' equity	22,365,670	30,567,975
Total liabilities and stockholders' equity	$ 29,189,012	$ 36,697,090